Health
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech
Georgetown researchers reported that combining BioXcel’s DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic…
When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…
Continue Reading
-
General18 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General20 hours agoBack-to-back rate cuts tipped when Reserve Bank meets
-
Noosa News20 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
Business23 hours agoThese ASX 200 shares could rise 55% to 65%